We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pegfilgrastim PBPC Mobilization Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00066092
First Posted: August 5, 2003
Last Update Posted: February 28, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Amgen
  Purpose
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.

Condition Intervention Phase
Lymphoma Hodgkin's Lymphoma Non-Hodgkin's Lymphoma Hematology Oncology Drug: pegfilgrastim 12 mg Drug: filgrastim Drug: pegfilgrastim 6 mg Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • CD34+ collection during the collection phase [ Time Frame: 10 days ]

Secondary Outcome Measures:
  • Time to ANC and platelet engraftment post-transplant [ Time Frame: 100 days ]

Enrollment: 41
Study Start Date: April 2003
Study Completion Date: October 2004
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pegfilgrastim 6 mg
Pegfilgrastim 6 mg given once for PBPC mobilization
Drug: pegfilgrastim 6 mg
Pegfilgrastim 6 mg given once for PBPC mobilization
Experimental: Pegfilgrastim 12 mg
Pegfilgrastim 12 mg given once for PBPC mobilization
Drug: pegfilgrastim 12 mg
Pegfilgrastim 12 mg given once for PBPC mobilization
Active Comparator: filgrastim
Filgrastim given daily for PBPC mobilization
Drug: filgrastim
Filgrastim given daily for PBPC mobilization

Detailed Description:
This is a research study for Hodgkin's Disease and Non-Hodgkin's Lymphoma (NHL) patients who will receive high-dose chemotherapy with autologous peripheral blood stem cell (PBSC or PBPC) transplant. The chemotherapy doses are high enough to severely suppress the bone marrow (where blood cells are made) and cause very low blood counts. A collection of stem cells (very young blood cells) followed by reinfusion to restore blood counts will be done to stimulate recovery of your blood counts. This procedure is called leukapheresis. Giving growth factors to patients is a method to increase the number of PBPC that can be collected during leukapheresis. This process of giving growth factors to patients is called mobilization (moving cells from the bone marrow to the peripheral blood where they can be collected). The purpose of this study is to determine if pegfilgrastim, an investigational drug, can safely and effectively mobilize stem cells. Filgrastim (also known as NEUPOGEN® or G-CSF) is approved by the FDA for stem cell mobilization. Pegfilgrastim is a modified version of Filgrastim that is longer acting.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Hodgkin's or non-Hodgkin's lymphoma patients suitable for an autologous PBPC transplant - No previous bone marrow or PBPC transplant
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00066092


Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Global Development Leader, Amgen Inc.
ClinicalTrials.gov Identifier: NCT00066092     History of Changes
Obsolete Identifiers: NCT00060229
Other Study ID Numbers: 20020112
First Submitted: August 4, 2003
First Posted: August 5, 2003
Last Update Posted: February 28, 2008
Last Verified: February 2008

Keywords provided by Amgen:
PBPC transplant
Hodgkin's Disease
Non-Hodgkin's Lymphoma
NHL
mobilization

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lenograstim
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs